Company Profile
Replimune Group Stock Price, News & Analysis
- Ticker:
- REPL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
12.86 USD (+8.71%)
Close
Last updated: August 6, 2026
732M USD
Market cap
Why the stock is moving
The latest monitored company update is “Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regim….” The corresponding closing-price reaction is not yet available.
Company overview
Oncolytic Immunotherapy Platform
Replimune develops tumor-directed immunotherapies based on engineered herpes simplex virus type 1. The RPx platform is designed to cause immunogenic tumor-cell death and stimulate a systemic antitumor immune response.
RP1
RP1 is engineered to express a fusogenic protein and GM-CSF and is the company’s lead candidate. A resubmitted BLA seeks approval in melanoma that has failed anti-PD-1 therapy, while the Phase 3 IGNYTE-3 trial serves as a global confirmatory study.
RP2
RP2 adds additional immune-stimulatory payloads to the RPx backbone. The registration-directed REVEAL Phase 2/3 trial is evaluating it in metastatic uveal melanoma, and separate studies address hepatocellular carcinoma and other liver-focused tumors.
Transplant-Associated Skin Cancer
The Phase 2 ARTACUS study evaluates RP1 monotherapy in cutaneous squamous cell carcinoma after organ transplantation. This program explores an oncolytic therapy in immunosuppressed patients for whom systemic checkpoint blockade may be difficult to use.
Future catalysts
FDA action on the resubmitted RP1 BLA targeted for April 10, 2026, followed by a potential launch if approved.
RP2 monotherapy data planned by year-end 2026.
Transition of the REVEAL uveal-melanoma study into Phase 2/3 expected in the first quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Replimune Group (REPL)?
Replimune Group (REPL) most recently closed at 12.86 USD, a +8.71% move versus the previous session.
What is the market cap of Replimune Group (REPL)?
Replimune Group currently has a market capitalization of 732M USD on BioPharmSignal.
What does Replimune Group do?
Oncolytic Immunotherapy Platform Replimune develops tumor-directed immunotherapies based on engineered herpes simplex virus type 1. The RPx platform is designed to cause immunogenic tumor-cell death and stimulate a systemic antitumor immune response. RP1 RP1 is engineered to express a fusogenic protein and GM-CSF and is the company’s lead candidate. A...
On which exchange is REPL stock listed?
Replimune Group (REPL) is associated with NASDAQ, United States, Biopharma.
What is GM-CSF?
RP1 RP1 is engineered to express a fusogenic protein and GM-CSF and is the company’s lead candidate.
Which conditions is Replimune Group targeting with GM-CSF?
Replimune Group is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Replimune Group describe recent progress with GM-CSF?
FDA action on the resubmitted RP1 BLA targeted for April 10, 2026, followed by a potential launch if approved. RP2 monotherapy data planned by year-end 2026. Transition of the REVEAL uveal-melanoma study into Phase 2/3 expected in the first quarter of 2027.
What is PD-1?
A resubmitted BLA seeks approval in melanoma that has failed anti-PD-1 therapy, while the Phase 3 IGNYTE-3 trial serves as a global confirmatory study.